Navigation Links
Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
Date:4/4/2011

CULVER CITY, Calif., April 4, 2011 /PRNewswire/ -- Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact, preclinical multimodality PET system provides researchers with the ability to non-invasively visualize and measure the biology of disease and therapeutic response over the course of a study.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

As molecular imaging becomes an essential tool for translational research, Sofie believes it is time for PET technology to be more widely accessible, cost-effective, and convenient for integration into a variety of labs.

To achieve this, PET must reduce its size and complexity while increasing usability and performance.  Furthermore, the valuable animal models at the heart of the study should have their physiology carefully maintained over the course of the experiment. GENISYS4 is the answer, utilizing new advances in detector architecture to offer unmatched sensitivity, and novel Docking Station and Imaging Chamber designs to provide safe conditions in an intuitive workflow experience. Compared to the traditional small animal PET systems that are three times the cost and ten times the size, GENISYS4 doesn't require specially trained personnel or expensive site planning to have researchers up and running with minimal cost and effort.

"GENISYS4 is launching an era of compact molecular imaging systems, just as PC companies have created a new world away from mainframes. At only 18 inches wide and 24 inches tall, GENISYS4 is the smallest PET imaging system in the industry, yet the most sensitive," said Patrick Phelps, Sofie Biosciences' President and Chief Executive Officer. "We are very excited to be the first to introduce a benchtop PET system as we join the efforts of other companies developing compact, simple, high-performance molecular imaging systems."

For additional information on Sofie's portfolio of technologies, please visit http://www.sofiebio.com.

About Sofie Biosciences 

Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.

For additional information contact Dr. Jennifer Cho at 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
7. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
8. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
9. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
10. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
11. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):